How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
End Stage Renal Disease Market
- By Treatment Modality: Hemodialysis, Peritoneal Dialysis, Kidney Transplantation, Conservative Management
- By Dialysis Access Type: Arteriovenous Fistula (AVF), Arteriovenous Graft (AVG), Central Venous Catheter (CVC)
- By Dialysis Setting: In-center Hemodialysis, Home Hemodialysis, Continuous Ambulatory Peritoneal Dialysis (CAPD), Automated Peritoneal Dialysis (APD)
- By Patient Age Group: Pediatric, Adult, Geriatric
- By Cause of End Stage Renal Disease: Diabetic Nephropathy, Hypertensive Nephrosclerosis, Glomerulonephritis, Polycystic Kidney Disease, Other Causes
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Hemodialysis leads By Treatment Modality at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 293 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the End Stage Renal Disease Market report
A complete, evidence-based study - 12 chapters and 123 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Treatment Modality 4
Dialysis Access Type 3
Dialysis Setting 4
Patient Age Group 3
Cause of End Stage Renal Disease 5
Companies profiled
Fresenius Medical Care AG & Co. KGaA
DaVita Inc.
Baxter International Inc.
B. Braun Melsungen AG
Nipro Corporation
Nikkiso Co. Ltd.
Asahi Kasei Corporation
Medtronic plc
AngioDynamics Inc.
Outset Medical Inc.
Toray Industries Inc.
Gambro (a subsidiary of Baxter)
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Fresenius Medical Care AG & Co. KGaA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →DaVita Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Baxter International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →B. Braun Melsungen AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Nipro Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Nikkiso Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Asahi Kasei Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Medtronic plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →AngioDynamics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Outset Medical Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Toray Industries Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Gambro (a subsidiary of Baxter)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →NxStage Medical
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Inc. (acquired by Fresenius)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Renalytix AI plc
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Dialife SAS
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,125M by 2033 · 10.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Hemodialysis46.9
- Peritoneal Dialysis23.7
- Kidney Transplantation9.0
- Conservative Management20.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$620.0M → $1,344M · 10.2%
Europe$432.1M → $862.6M · 9.0%
Asia Pacific$394.5M → $935.0M · 11.4%
Latin America$244.2M → $574.6M · 11.3%
Middle East and Africa$187.9M → $440.7M · 11.2%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.282026
10.302027
10.302028
10.312029
10.332030
10.342031
10.352032
10.372033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Fresenius Medical Care AG & Co. KGaA18.5
- DaVita Inc.20.2
- Baxter International Inc.10.8
- B. Braun Melsungen AG8.1
- Nipro Corporation10.7
- Nikkiso Co. Ltd.3.8
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Modality21.1%
Dialysis Access Type14.3%
Dialysis Setting27.8%
Patient Age Group21.3%
Cause of End Stage Renal Disease15.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.3
- Europe20.8
- Asia Pacific22.5
- Latin America13.8
- Middle East and Africa10.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Fresenius Medical Care AG & Co. KGaA | 98 | 88 | 77 | 81 | 79 | 99 | 87 |
| DaVita Inc. | 91 | 82 | 87 | 81 | 69 | 70 | 80 |
| Baxter International Inc. | 71 | 73 | 63 | 83 | 80 | 87 | 76 |
| B. Braun Melsungen AG | 61 | 63 | 79 | 74 | 64 | 62 | 67 |
| Nipro Corporation | 53 | 77 | 66 | 76 | 65 | 71 | 68 |
| Nikkiso Co. Ltd. | 68 | 59 | 71 | 70 | 46 | 62 | 63 |
| Asahi Kasei Corporation | 47 | 63 | 57 | 42 | 59 | 45 | 52 |
| Medtronic plc | 46 | 47 | 40 | 47 | 53 | 58 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Fresenius Medical Care AG & Co. KGaA
- DaVita Inc.
- Baxter International Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Fresenius Medical Care AG & Co. KGaA | ✓ | ✓ | ◐ | ◐ | ◐ | ✓ |
| DaVita Inc. | ✓ | ◐ | ◐ | ◐ | ✓ | ◐ |
| Baxter International Inc. | ✓ | ✓ | ◐ | ✓ | ◐ | ✓ |
| B. Braun Melsungen AG | ◐ | ◐ | ◐ | ✓ | ◐ | ✓ |
| Nipro Corporation | ◐ | ✓ | − | ✓ | ✓ | ◐ |
| Nikkiso Co. Ltd. | ✓ | − | ✓ | ◐ | − | ✓ |
| Asahi Kasei Corporation | − | ◐ | ◐ | − | − | ◐ |
| Medtronic plc | − | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Fresenius Medical Care AG & Co. KGaA87
2DaVita Inc.80
3Baxter International Inc.76
4Nipro Corporation68
5B. Braun Melsungen AG67
6Nikkiso Co. Ltd.63
7Asahi Kasei Corporation52
8Medtronic plc49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Fresenius Medical Care AG & Co. KGaADaVita Inc.
Challenger3
Strong scale, closing on the leaders.
Baxter International Inc.B. Braun Melsungen AGNipro Corporation
Contender1
Focused players with pockets of strength.
Nikkiso Co. Ltd.
Niche2
Specialists in a single segment or region.
Asahi Kasei CorporationMedtronic plc
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Modality in North America, then scale across End Stage Renal Disease Market — a $556M beachhead inside a $7.67B market.
Beachhead (SOM)$556Mobtainable near-term
Serviceable (SAM)$3.18Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Hemodialysis
Best fit — highest urgency & budget in Treatment Modality.
Economic buyer79 fit
Peritoneal Dialysis
Strong fit — clear ROI and a fast path to value.
End user65 fit
Kidney Transplantation
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Modality in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Dialysis Access Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Dialysis Setting
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel30%
Digital / self-serve18%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Modality leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win End Stage Renal Disease Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified24%
Evaluation15%
Closed-won5%
$18.5KCAC
$106KLTV
5.7:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
End Stage Renal Disease Market is a high-growth opportunity — $12.4B by 2033, compounding at 11.3%.
TAM · 2025$5.29Btoday
TAM · 2033$12.4Bforecast
CAGR11.3%2027–2033
Cumulative$75.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$12.4BTotal addressable market
SAM$4.39BServiceable available market
SOM$912MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.3% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Modality.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Modality moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$12.4BLarge & growingTAM by 2033 at 11.3% CAGR
$4.39BServiceable nowreachable with today’s model
$912MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$9.71BBear7.3% CAGR
$12.4BBase11.3% CAGR
$15.9BBull14.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Dialysis Access Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
End Stage Renal Disease Market — a $2.10B market by 2033. Plan: grow share from 9.2% to 14.7%.
Market size · 2033$2.10Btotal addressable
Market CAGR8.5%2027–2033
Target share14.7%from 9.2% today
Revenue ambition$308Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.2% | 14.7% | Ahead |
| Revenue | $197M | $308M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 30.9% | 38.3% | Behind |
| Customer retention | 86.7% | 93.7% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Modality
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Dialysis Access Type capability
A defensible second engine — invest in Dialysis Access Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Modality share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Dialysis Access Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $43M capacity & capability investment
- Greenlight bolt-on M&A in Dialysis Access Type
- Authorise North America expansion plan
- Fund R&D program for Treatment Modality leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the End Stage Renal Disease Market conversation — a $4.32B market you can size, segment and defend in minutes.
Market size · 2033$4.32Btotal opportunity
Growth4.3%CAGR to 2033
Addressable buyers1,685+accounts in scope
Typical ROI6.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Modality
Goal Grow share in Treatment Modality
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.1×return on cost, year one
< 3 mopayback period
$86K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Fresenius Medical Care AG & Co. KGaADaVita Inc.Baxter International Inc.B. Braun Melsungen AGNipro CorporationNikkiso Co. Ltd.Asahi Kasei CorporationMedtronic plc+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your End Stage Renal Disease Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
End Stage Renal Disease Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →End Stage Renal Disease (ESRD) Treatment Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportEnd Stage Renal Disease (ESRD) Therapy Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportEnd-Stage Renal Disease (ESRD) Device Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportEnd Stage Renal Disease Drug Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportTermite Drug Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportEnd-Stage Kidney Disease Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportFlow Chemistry Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportSilicone Gel Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportVanillic Acid (CAS 121-34-6) Market
Market size, share, segmentation and regional forecast.
$724M market · 2025 base year
View reportEndovenous Laser Treatment Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportMagnesium Ethoxide Market
Market size, share, segmentation and regional forecast.
$624M market · 2025 base year
View reportEndovenous Laser Ablation Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.